Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$273 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.9
Industry P/E
--
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-29
Face value
--
Shares outstanding
12,969,800
CFO
$-339.13 Mln
EBITDA
$-420.07 Mln
Net Profit
$-416.09 Mln
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
---|---|---|---|---|---|---|---|
Cidara Therapeutics (CDTX)
| 67.2 | 74.9 | 100.0 | 286.8 | 339.4 | 62.8 | 11.5 |
BSE Sensex*
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
---|---|---|---|---|---|---|---|
Cidara Therapeutics (CDTX)
| 3,189.6 | 5.0 | -40.5 | -36.5 | -47.9 | 63.4 | -65.2 |
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
---|---|---|---|---|---|---|---|---|
Cidara Therapeutics (CDTX)
|
45.0 | 272.6 | 0.3 | -180.7 | -35,750.3 | -140.5 | -- | 1.9 |
49.3 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
128.4 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
147.4 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
52.5 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
43.4 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
52.8 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
308.6 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
25.7 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
125.8 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the... echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 Read more
President, CEO & Executive Director
Dr. Jeffrey L. Stein Ph.D.
President, CEO & Executive Director
Dr. Jeffrey L. Stein Ph.D.
Headquarters
San Diego, CA
Website
The total asset value of Cidara Therapeutics Inc (CDTX) stood at $ 241 Mln as on 31-Mar-25
The share price of Cidara Therapeutics Inc (CDTX) is $44.95 (NASDAQ) as of 23-Jun-2025 16:28 EDT. Cidara Therapeutics Inc (CDTX) has given a return of 339.36% in the last 3 years.
Cidara Therapeutics Inc (CDTX) has a market capitalisation of $ 273 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cidara Therapeutics Inc (CDTX) is 1.92 times as on 23-Jun-2025, a 31% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of Cidara Therapeutics Inc (CDTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cidara Therapeutics Inc (CDTX) and enter the required number of quantities and click on buy to purchase the shares of Cidara Therapeutics Inc (CDTX).
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
The CEO & director of Dr. Jeffrey L. Stein Ph.D.. is Cidara Therapeutics Inc (CDTX), and CFO & Sr. VP is Dr. Jeffrey L. Stein Ph.D..
There is no promoter pledging in Cidara Therapeutics Inc (CDTX).
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
1,260
|
|
1,128
|
|
991
|
|
988
|
|
870
|
|
829
|
|
809
|
|
742
|
|
664
|
Cidara Therapeutics Inc. (CDTX) | Ratios |
---|---|
Return on equity(%)
|
-140.48
|
Operating margin(%)
|
-35750.33
|
Net Margin(%)
|
-59845.03
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cidara Therapeutics Inc (CDTX) was $0 Mln.